Trial record 3 of 32 for:
Antiphospholipid Syndrome
Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study
This study is currently recruiting participants.
Verified November 2012 by University of California, Davis
Sponsor:
University of California, Davis
Collaborator:
The Slovenian Ministry of Higher Education, Science and Technology
Information provided by (Responsible Party):
Lavjay Butani, MD, University of California, Davis
ClinicalTrials.gov Identifier:
NCT00616317
First received: February 4, 2008
Last updated: November 30, 2012
Last verified: November 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to gather information about causes and treatment of Antiphospholipid Syndrome.
| Condition |
|---|
|
Antiphospholipid Syndrome |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
| Official Title: | Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study |
Further study details as provided by University of California, Davis:
Primary Outcome Measures:
- Long term survival [ Time Frame: 10 year ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 50 |
| Study Start Date: | September 2006 |
| Estimated Study Completion Date: | January 2015 |
| Estimated Primary Completion Date: | January 2015 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | up to 18 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Pediatric Nephrology Clinic at University of California, Davis
Criteria
Inclusion Criteria:
- 18 years of age or younger at the onset of disease
- Presence of Vascular Thrombosis
- UC Davis patient
- Presence of at least one Laboratory criteria including: Anticardiolipin antibody, Anti-B glycoprotein-I antibody or Lupus anticoagulant in plasma
Exclusion Criteria:
- Infants born to mothers with APS
- Infants with congenital thrombophilia
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00616317
Contacts
| Contact: Lavjay Butani | (916) 734-8118 |
Locations
| United States, California | |
| UC Davis Medical Center | Recruiting |
| Sacramento, California, United States, 95817 | |
Sponsors and Collaborators
University of California, Davis
The Slovenian Ministry of Higher Education, Science and Technology
Investigators
| Principal Investigator: | Lavjay Butani, M.D. | University of California, Davis |
More Information
Additional Information:
Related Info 
No publications provided
| Responsible Party: | Lavjay Butani, MD, Associate Professor, University of California, Davis |
| ClinicalTrials.gov Identifier: | NCT00616317 History of Changes |
| Other Study ID Numbers: | 200614666-1 |
| Study First Received: | February 4, 2008 |
| Last Updated: | November 30, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of California, Davis:
|
Antiphospholipid Syndrome |
Additional relevant MeSH terms:
|
Antiphospholipid Syndrome Autoimmune Diseases Immune System Diseases |
ClinicalTrials.gov processed this record on May 19, 2013